August 13, 2020 -- The U.S. Food and Drug Administration (FDA) has granted fast track designation to Akeso for Ak104, a bispecific antibody, as a monotherapy for the treatment of patients with recurrent or metastatic squamous cervical cancer.
Ak104 is a humanized immunoglobulin G (IgG1) tetrameric bispecific antibody drug candidate designed to preferentially bind to tumor infiltrating lymphocytes. It targets two immune checkpoint molecules -- programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) -- simultaneously. The antibody was developed using Akeso's proprietary Tetrabody technology platform. The therapy is currently undergoing phase Ib/II and phase II clinical trials in China and Australia for multiple indications.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
